scholarly journals Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients

2019 ◽  
Vol 132 (22) ◽  
pp. 2684-2689
Author(s):  
Gan-Sheng Xie ◽  
Gang Li ◽  
Yu Li ◽  
Jin-Xian Pu ◽  
Yu-Hua Huang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Plasma Fibrinogen ◽  
Newly Diagnosed ◽  
Metastatic Burden ◽  
Pre Treatment

598: Increased Risk of Newly Diagnosed Comorbidities in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

2007 ◽  
Vol 177 (4S) ◽  
pp. 200-200 ◽  
Author(s):  
Andrea Gallina ◽  
Pierre I. Karakiewicz ◽  
Jochen Walz ◽  
Claudio Jeldres ◽  
Quoc-Dien Trinh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Increased Risk

289: Assessment of Indirect Costs of Newly Diagnosed Prostate Cancer Patients

2007 ◽  
Vol 177 (4S) ◽  
pp. 97-97
Author(s):  
Ravishankar Jayavedappa ◽  
Sumedha Chhatre ◽  
Richard Whittington ◽  
Alan J. Wein ◽  
S. Bruce Malkowicz
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Indirect Costs ◽  
Newly Diagnosed

scholarly journals Recent trend of ADT in newly‐diagnosed prostate cancer patients: comparing between high‐ and middle income Asian countries

2021 ◽  
Author(s):  
Jasmine Lim ◽  
Mizuki Onozawa ◽  
Marniza Saad ◽  
Teng Aik Ong ◽  
Rohan Malek ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Recent Trend ◽  
Newly Diagnosed ◽  
Asian Countries ◽  
Middle Income

scholarly journals Is there a correlation between the aggressiveness of chronic asymptomatic prostatitis NIH category IV and the Gleason score in patients with prostate cancer?

2019 ◽  
Vol 14 (11) ◽  
Author(s):  
Erdogan Aglamis ◽  
Cavit Ceylan ◽  
Mustafa Akin
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Gleason Score ◽  
Needle Biopsy ◽  
Newly Diagnosed ◽  
Prostate Needle Biopsy ◽  
Retrospective Design ◽  
Biopsy Specimens ◽  
Grade 3 ◽  
Prostatic Inflammation

Introduction: We evaluated the correlation between the International Society of Urological Pathology (ISUP) grades and the aggressiveness grades of prostate inflammation in newly diagnosed prostate cancer patients with chronic asymptomatic prostatitis National Institiutes of Health (NIH) category IV (CAPNIHIV). Methods: The study comprised 357 consecutive patients with prostate cancer in whom a cancer diagnosis had been made via a prostate needle biopsy. Histological sections of the prostate biopsy specimens of the patients were reviewed and scored. Prostatic inflammation was scored using the aggressiveness grade of inflammation. The associations between the ISUP grades and the aggressiveness grades of inflammation were analyzed using logistic regression. The limitations of the study were its retrospective design and the limited number of cases. Results: In 110 (31%) patients, CAPNIHIV was detected: 56 (51%) patients had a grade 0 aggressiveness score, 34 (31%) patients had a grade 1 aggressiveness score, and 20 (18%) patients had a grade 2 aggressiveness score. The patients who had prostatic inflammation had a 1.65 times (95% confidence interval [CI] 1.05–2.61) greater likelihood of a high ISUP grade (grade ≥3) compared with the patients who did not have prostatic inflammation. The association between the ISUP grade and the aggressiveness grade of inflammation was more pronounced for a grade 2 aggressiveness score (n= 20; odds ratio 2.97; 95% CI 1.14–7.71). Conclusions: In prostate cancer patients with CAPNIHIV, there was a positive correlation between the inflammation aggressiveness grade and the ISUP grade. The aggressiveness of intraprostatic inflammation may be an important morphological factor affecting the Gleason score.

scholarly journals Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer

Cancers ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 160 ◽  
Author(s):  
Wojciech A. Cieślikowski ◽  
Joanna Budna-Tukan ◽  
Monika Świerczewska ◽  
Agnieszka Ida ◽  
Michał Hrab ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Disease ◽  
Newly Diagnosed ◽  
High Risk Prostate Cancer ◽  
Intergroup Comparison ◽  
Risk Prostate Cancer

The aim of this study was to investigate whether the enumeration of circulating tumor cells (CTCs) in blood can differentiate between true localized and metastatic prostate cancer. A cross-sectional study of 104 prostate cancer patients with newly diagnosed high-risk prostate cancer was conducted. In total, 19 patients presented metastatic disease and 85 were diagnosed with localized disease. Analyses included intergroup comparison of CTC counts, determined using the CellSearch® system, EPISPOT assay and GILUPI CellCollector®, and ROC analysis verifying the accuracy of CTC count as a maker of disseminated prostate cancer. The vast majority (94.7%) of patients with advanced-stage cancer tested positively for CTCs in at least one of the assays. However, significantly higher CTC counts were determined with the CellSearch® system compared to EPISPOT assay and GILUPI CellCollector®. Identification of ≥4 CTCs with the CellSearch® system was the most accurate predictor of metastatic disease (sensitivity 0.500; specificity 0.900; AUC (95% CI) 0.760 (0.613–0.908). Furthermore, we tried to create a model to enhance the specificity and sensitivity of metastatic prediction with CTC counts by incorporating patient’s clinical data, including PSA serum levels, Gleason score and clinical stage. The composite biomarker panel achieved the following performance: sensitivity, 0.611; specificity, 0.971; AUC (95% CI), 0.901 (0.810–0.993). Thus, although the sensitivity of CTC detection needs to be further increased, our findings suggest that high CTC counts might contribute to the identification of high-risk prostate cancer patients with occult metastases at the time of diagnosis.

Clinical significance of plasma fibrinogen level in patients with prostate cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e16077-e16077
Author(s):  
Xiao-Kun Ma ◽  
Jing-Yun Wen ◽  
Zhan-Hong Chen ◽  
Qu Lin ◽  
Xing Li ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Gleason Score ◽  
Locally Advanced ◽  
Specific Antigen ◽  
Tnm Stage ◽  
Plasma Fibrinogen ◽  
T State ◽  
Coagulation Analyzer ◽  
Worse Prognosis

e16077 Background: Most of malignant tumor patients have hypercoagulable state with plasma fibrinogen (Fib) levels increased. In this study, we aimed to investigate correlation of plasma Fib with routine prognostic factors of prostate cancer patients, including Gleason score, prostate specific antigen (PSA), TNM 7th Stage. Methods: From January 2007 to December 2012, 107 patients with prostate cancer and 44 cases of benign prostatic hyperplasia (BPH) were included in our study. Automated coagulation analyzer was used to determine the plasma fibrinogen levels. Results: The patients presented a mean age of 70.6 years, a mean PSA level of 28.73 ng/ml, clinically localized prostate cancer in 47 cases, locally advanced condition in 27cases, and distant metastatic disease in 33 cases. The fibrinogen levels were increased in cancer patients compared to that in patients with BPH (P = 0.031). Higher fibrinogen levels related to metastasis, higher TNM stage and increased PSA (p = 0.000, 0.041 and 0.004 respectively). Fib levels were irrelevant to T state, N state, and Gleason score. Conclusions: Prostate cancer patients displayed increased Fib levels. Plasma Fib is significantly increased in patients with higher PSA level,worse TNM stage and distant metastasis. The patients with high Fib might presented relative worse prognosis and should be monitored closely. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document